MediaAbolerIS Pharma2020-12-15T13:30:03+00:00

News & Media

PRESS RELEASE (01/12/2020) – AbolerIS Pharma signed an exclusive world-wide license with Ouest Valorisation to develop new first-in-class anti-CD45RC antibodies. Read in English . Read in French.
PRESS RELEASE (04/11/2020) – AbolerIS Pharma Raises €2.5M in Seed Financing from Newton Biocapital and Turenne Santé/Sham Innovation Santé. Read in English . Read in French.